Identifying Novel Targets for Non-Small Cell Lung Cancer – Just How Novel Are They?

Drug Discovery and Development, Life Sciences, Pharmaceutical,
  • Tuesday, September 18, 2018 | 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
  • 60 min

Despite significant advances in the treatment of lung cancer, this disease continues to be the leading cause of cancer death among men and the second leading cause among women, worldwide. In the European Union alone, approximately 191,900 men and 87,500 women were expected to die of lung cancer in 2015 (age-standardized mortality rate 35.98 and 14.24 per 100,000 in men and women, respectively). In the absence of curative therapies, the objectives of lung cancer treatment are prolongation of survival and the achievement and maintenance of a good quality of life for as long as possible. While this has led to numerous treatments coming to market over the years including surgery, radiotherapy, chemotherapy, immunotherapy or any combination thereof, it leaves an opportunity to develop new treatments that build on past findings and continuously improve the range of outcomes for potential patients.

Unfortunately, many scientists struggle when it comes to compiling research conducted on previous targets, leading them to continue down pathways that have already been proven to be ineffective. This is why being able to efficiently identify and prioritize novel targets for all diseases, and especially lung cancer, has become an increasingly important step in the drug development process.

In this webinar, featured speakers will demonstrate new ways in which publicly available non-small-cell lung cancer (NSCLC) datasets can be examined in order to find novel approaches to targeting the disease. Specifically, they will discuss how quick and easy it can be (with the right tools) to examine the novelty of your target and the importance of doing so. In the end, the speakers will use these tools to find evidence for core known tumour suppressive mechanisms to be potential targets for NSCLC.

What you will learn:

  • The latest trends in lung cancer research
  • New techniques for identifying targets, specifically using gene expression analysis
  • How you can prioritize targets for cancer research more efficiently

Speakers

Leo Lafferty-Whyte, PhD, Proposition Manager, Clarivate Analytics

Dr. Leo Lafferty-Whyte is the Proposition Manager for Clarivate Analytics Discovery and Preclinical Products. With a background in genetics, immunology and cancer bioinformatics, Leo has 12 scientific publications to his name. Within Clarivate, he helps to align the needs of scientists across the globe with the company’s strategy.

Message Presenter

Sonya Novikova, Solution Scientist, Life Sciences, Clarivate Analytics

Sonya Novikova is the Solution Scientist in Discovery and Preclinical Research, Life Sciences, at Clarivate Analytics. In her role, she searches for solutions to address customers’ needs in early drug and biomarker discovery and preclinical research. Sonya has over 10 years of experience in the life sciences industry, having extensive knowledge of molecular signaling pathways & networks, OMICs data analysis and interpretation, and disease mechanisms reconstruction.

Message Presenter

Who Should Attend?

  • Drug discovery scientists
  • Translational research scientists
  • Bioinformaticians
  • Biologists

What You Will Learn

  • The latest trends in lung cancer research
  • New techniques for identifying targets, specifically using gene expression analysis
  • How you can prioritize targets for cancer research more efficiently

Xtalks Partner

Clarivate Analytics

Clarivate Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns wellknown brands that include Web of Science™, Cortellis™, Thomson Innovation™, Derwent World Patents Index™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account